Show simple item record

dc.contributor.authorHughes, Stephen Fôn; orcid: 0000-0001-6558-9037; email: Stephen.hughes6@wales.nhs.uk
dc.contributor.authorMoyes, Alyson Jayne
dc.contributor.authorLamb, Rebecca May
dc.contributor.authorElla-tongwiis, Peter
dc.contributor.authorBell, Christopher
dc.contributor.authorMoussa, Ahmed
dc.contributor.authorShergill, Iqbal
dc.date.accessioned2020-09-25T16:31:27Z
dc.date.available2020-09-25T16:31:27Z
dc.date.issued2020-08-14
dc.date.submitted2020-04-27
dc.identifier.citationHughes, S. F., Moyes, A. J., Lamb, R. M., Ella-Tongwiis, P., Bell, C., Moussa, A., & Shergill, I. (2020). The role of specific biomarkers, as predictors of post-operative complications following flexible ureterorenoscopy (FURS), for the treatment of kidney stones: a single-centre observational clinical pilot-study in 37 patients. BMC urology, 20(1), 1-10.
dc.identifier.urihttp://hdl.handle.net/10034/623716
dc.description.abstractAbstract: Background: The number of patients diagnosed and subsequently treated for kidney stones is increasing, and as such the number of post-operative complications is likely to increase. At present, little is known about the role of specific biomarkers, following flexible ureterorenoscopy (FURS) for the surgical treatment of kidney stones. The main aim of the study was to evaluate the role of kidney and infection biomarkers, in patients undergoing FURS. Methods: Included were 37 patients (24 males, 13 females), who underwent elective FURS, for the treatment of kidney stones. Venous blood samples were collected from each patient: pre-operatively, and at 30 min, 2 and 4 h post-operatively. Changes to kidney (NGAL, Cystatin-C) and infection (MPO, PCT) biomarkers was quantified by means of ELISA, Biomerieux mini-vidas and Konelab 20 analysers. Results: Four patients developed post-operative complications (3 - UTIs with urinary retention, 1 - urosepsis. NGAL concentration increased significantly following FURS (p = 0.034). Although no significant changes were seen in Cystatin C, MPO and PCT (p ≥ 0.05) some key clinical observation were noted. Limiting factors for this study were the small number of patients recruited and restriction in blood sampling beyond 4 h. Conclusions: Although not confirmative, changes seen to biomarkers such as Cystatin C, NGAL and MPO in our observational clinical pilot-study may warrant further investigation, involving larger cohorts, to fully understand the role of these biomarkers and their potential association with post-operative complications which can develop following FURS.
dc.languageen
dc.publisherBioMed Central
dc.rightsLicence for this article: https://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 1471-2490
dc.subjectPre-clinical and basic research
dc.subjectFlexible Ureterenoscopy
dc.subject(FURS)
dc.subjectKidney stones
dc.subjectBiomarkers
dc.subjectInfection
dc.subjectPost-operative complications
dc.titleThe role of specific biomarkers, as predictors of post-operative complications following flexible ureterorenoscopy (FURS), for the treatment of kidney stones: a single-centre observational clinical pilot-study in 37 patients
dc.typearticle
dc.date.updated2020-09-25T16:31:26Z
dc.date.accepted2020-08-04


Files in this item

Thumbnail
Name:
12894_2020_Article_693.pdf
Size:
1.328Mb
Format:
PDF
Thumbnail
Name:
12894_2020_Article_693_nlm.xml
Size:
71.68Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record